AstraZeneca results: FY and Q4 2025
View original at finance.yahoo.comAstraZeneca results: FY and Q4 2025 Strong commercial performance and excellent pipeline delivery in a continuing catalyst-rich period CAMBRIDGE, England, February 10, 2026--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary FY 2025 % Change Q4 2025 % Change $m Actual CER1 $m Actual CER - Product Sales 55,573 9 9 14…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Harmonised listing structure across NYSE, London, and Stockholm exchanges enables more shareholders to participate in the company's exciting future
80% confidenceCore Tax rate is expected to be between 18-22% for FY 2026
80% confidenceThe momentum across our company is continuing in 2026 and we are looking forward to the results of more than 20 Phase 3 trial readouts this year. We have more than 100 Phase 3 studies ongoing.
80% confidenceCore EPS is expected to increase by a low double-digit percentage for FY 2026 at CER
80% confidenceIn 2025 we saw strong commercial performance across our therapy areas and excellent pipeline delivery. We announced the results of 16 positive Phase 3 studies during the year and now have 16 blockbuster medicines.
80% confidenceTotal Revenue is expected to increase by a mid-to-high single-digit percentage for FY 2026 at CER
80% confidenceTransformative technologies including substantial and growing number of trials have the potential to revolutionise outcomes for patients and drive growth well beyond 2030
80% confidence
Data points we hold from this source
| AstraZeneca AB · phase 3 trials ongoing | 100 trials |
| AstraZeneca AB · positive phase 3 readouts | 16 trials |
| AstraZeneca AB · product revenue | 58640 million_USD |
| AstraZeneca AB · product sales | 55573 million_USD |
| AstraZeneca AB · core sga expense | 4453 million_USD |
| AstraZeneca AB · rd expense | 3862 million_USD |
| AstraZeneca AB · operating profit | 2978 million_USD |
| AstraZeneca AB · revenue | 58739 million_USD |
| AstraZeneca AB · revenue | 15503 million_USD |
| AstraZeneca AB · second interim dividend | 2.17 USD |
| AstraZeneca AB · sga expense | 5492 million_USD |
| AstraZeneca AB · core operating profit | 4098 million_USD |
| AstraZeneca AB · core operating margin | 26 percent |
| AstraZeneca AB · dividend per share | 3.20 USD |
| AstraZeneca AB · gross margin | 80 percent |
| AstraZeneca AB · blockbuster medicines | 16 products |
| AstraZeneca AB · core tax rate | 14 percent |
| AstraZeneca AB · net finance expense | 349 million_USD |
| AstraZeneca AB · operating margin | 19 percent |
| AstraZeneca AB · tax rate | 11 percent |
| AstraZeneca AB · core eps | 9.16 USD |
| AstraZeneca AB · alliance revenue | 959 million_USD |
| AstraZeneca AB · collaboration revenue | 99 million_USD |
| AstraZeneca AB · approvals in major regions | 43 approvals |
| AstraZeneca AB · core rd expense | 3731 million_USD |